• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Peering Into Abiomed's Recent Short Interest

    11/17/22 10:12:26 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care
    Get the next $ABMD alert in real time by email

    Abiomed's (NASDAQ:ABMD) short percent of float has risen 6.62% since its last report. The company recently reported that it has 2.08 million shares sold short, which is 5.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.8 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Abiomed Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Abiomed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

    Comparing Abiomed's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Abiomed's peer group average for short interest as a percentage of float is 3.29%, which means the company has more short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it..

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $ABMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABMD

    DatePrice TargetRatingAnalyst
    11/2/2022$235.00 → $380.00Underweight → Equal-Weight
    Morgan Stanley
    11/2/2022$355.00 → $388.00Buy → Hold
    Deutsche Bank
    10/13/2022$300.00Buy
    Mizuho
    4/6/2022$330.00Peer Perform
    Wolfe Research
    2/4/2022$292.00 → $275.00Underweight
    Morgan Stanley
    2/4/2022$345.00 → $325.00Market Perform
    SVB Leerink
    1/7/2022$269.00 → $292.00Underweight
    Morgan Stanley
    8/6/2021$335.00 → $375.00Market Perform
    SVB Leerink
    More analyst ratings

    $ABMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Sutter Martin P returned 123,370 shares to the company, closing all direct ownership in the company

    4 - ABIOMED INC (0000815094) (Issuer)

    12/27/22 8:47:48 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Puhy Dorothy E returned 14,590 shares to the company, closing all direct ownership in the company

    4 - ABIOMED INC (0000815094) (Issuer)

    12/27/22 8:44:35 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Trapp Todd A returned 14,166 shares to the company, closing all direct ownership in the company

    4 - ABIOMED INC (0000815094) (Issuer)

    12/27/22 8:41:11 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    $ABMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Abiomed upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Abiomed from Underweight to Equal-Weight and set a new price target of $380.00 from $235.00 previously

    11/2/22 9:11:07 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    Abiomed downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Abiomed from Buy to Hold and set a new price target of $388.00 from $355.00 previously

    11/2/22 6:09:28 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    Mizuho initiated coverage on Abiomed with a new price target

    Mizuho initiated coverage of Abiomed with a rating of Buy and set a new price target of $300.00

    10/13/22 7:17:59 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    $ABMD
    SEC Filings

    View All

    SEC Form 15-12G filed by ABIOMED Inc.

    15-12G - ABIOMED INC (0000815094) (Filer)

    1/3/23 8:30:58 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by ABIOMED Inc.

    S-8 POS - ABIOMED INC (0000815094) (Filer)

    12/22/22 4:46:31 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by ABIOMED Inc.

    S-8 POS - ABIOMED INC (0000815094) (Filer)

    12/22/22 4:46:02 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    $ABMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    7/12/23 9:00:00 AM ET
    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care

    FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

    Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt

    12/21/22 9:00:00 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400

    NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion

    12/19/22 6:35:00 PM ET
    $ABMD
    $JNJ
    $SMCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Computer Manufacturing

    $ABMD
    Financials

    Live finance-specific insights

    View All

    Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

    ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa

    11/1/22 7:00:00 AM ET
    $ABMD
    $JNJ
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Johnson & Johnson to Acquire Abiomed

    Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil

    11/1/22 6:30:00 AM ET
    $ABMD
    $JNJ
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

    Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The repla

    10/13/22 7:00:00 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    $ABMD
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    7/12/23 9:00:00 AM ET
    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care

    MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

    Succeeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed's MedTech Conference 2022, which is taking place through Oct. 26 at the Boston Convention and Exhibition Center. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and will assume the role on January 1, 2023. This press release features multimedia. View the full release here: https

    10/24/22 12:00:00 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    Dr. Paula A. Johnson Joins Abiomed Board of Directors

    Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/Dr. Paula A. Johnson joins the Abiomed Board of Directors (Photo: Business Wire) "Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women," said Michae

    4/28/21 8:03:00 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    $ABMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

    SC 13G/A - ABIOMED INC (0000815094) (Subject)

    1/6/23 6:39:54 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by ABIOMED Inc.

    SC 13G - ABIOMED INC (0000815094) (Subject)

    12/29/22 4:03:01 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

    SC 13G/A - ABIOMED INC (0000815094) (Subject)

    2/9/22 3:16:00 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care